Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol by Alonso-Coello, Pablo et al.
Alonso-Coello et al. BMC Pregnancy and Childbirth 2012, 12:40
http://www.biomedcentral.com/1471-2393/12/40STUDY PROTOCOL Open AccessEvaluating patient values and preferences for
thromboprophylaxis decision making during
pregnancy: a study protocol
Pablo Alonso-Coello1, Shanil Ebrahim2, Gordon H Guyatt2,3*, Kari AO Tikkinen2,4, Mark H Eckman5,
Ignacio Neumann2,6, Sarah D McDonald7, Elie A Akl2,8 and Shannon M Bates3,9Abstract
Background: Pregnant women with prior venous thromboembolism (VTE) are at risk of recurrence. Low molecular
weight heparin (LWMH) reduces the risk of pregnancy-related VTE. LMWH prophylaxis is, however, inconvenient,
uncomfortable, costly, medicalizes pregnancy, and may be associated with increased risks of obstetrical bleeding.
Further, there is uncertainty in the estimates of both the baseline risk of pregnancy-related recurrent VTE and the
effects of antepartum LMWH prophylaxis. The values and treatment preferences of pregnant women, crucial when
making recommendations for prophylaxis, are currently unknown. The objective of this study is to address this gap
in knowledge.
Methods: We will perform a multi-center cross-sectional interview study in Canada, USA, Norway and Finland. The
study population will consist of 100 women with a history of lower extremity deep vein thrombosis (DVT) or
pulmonary embolism (PE), and who are either pregnant, planning pregnancy, or may in the future consider
pregnancy (women between 18 and 45 years). We will exclude individuals who are on full dose anticoagulation or
thromboprophylaxis, who have undergone surgical sterilization, or whose partners have undergone vasectomy. We
will determine each participant's willingness to receive LMWH prophylaxis during pregnancy through direct choice
exercises based on real life and hypothetical scenarios, preference-elicitation using a visual analog scale (“feeling
thermometer”), and a probability trade-off exercise. The primary outcome will be the minimum reduction
(threshold) in VTE risk at which women change from declining to accepting LMWH prophylaxis. We will explore
possible determinants of this choice, including educational attainment, the characteristics of the women’s prior VTE,
and prior experience with LMWH. We will determine the utilities that women place on the burden of LMWH
prophylaxis, pregnancy-related DVT, pregnancy-related PE and pregnancy-related hemorrhage. We will generate a
“personalized decision analysis” using participants’ utilities and their personalized risk of recurrent VTE as inputs to a
decision analytic model. We will compare the personalized decision analysis to the participant’s stated choice.
Discussion: The preferences of pregnant women at risk of VTE with respect to the use of antithrombotic therapy
remain unexplored. This research will provide explicit, quantitative expressions of women's valuations of health
states related to recurrent VTE and its prevention with LMWH. This information will be crucial for both guideline
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Pregnancy-associated venous thromboembolism (VTE),
which may manifest as pulmonary embolism (PE) or
deep vein thrombosis (DVT), is an important cause of
maternal morbidity [1]. PE remains the leading cause of
mortality in developed countries, accounting for ap-
proximately 30% of all maternal deaths [2-5].
Although cohort studies have consistently demon-
strated that pregnant women with prior VTE are at
increased risk of recurrence [6], they have varied consid-
erably in their estimates of magnitude of risk [7-11]. In
the largest prospective study of 125 pregnant women
with a single previous episode of objectively diagnosed
VTE in whom antepartum heparin was withheld [9], the
incidence of antepartum recurrence was 2.4% (95% CI of
0.2 to 6.9%). In subsequently published large retrospect-
ive cohort studies, the probability of antepartum VTE in
women not given antepartum prophylaxis was approxi-
mately 6% [12,13]. The inclusion of women with more
than one prior episode of VTE as well as women with
pregnancies ending in loss, and the failure to independ-
ently adjudicate recurrent events might account for the
higher risk of recurrence observed in these retrospective
studies. Despite the inconsistency, the overall risk of
antepartum recurrent VTE in all studies was less than
10% and confidence intervals around the risk estimates
of individual studies were overlapping.
The risk of recurrent VTE in the non-pregnant popu-
lation is lowest among women whose thrombosis was
provoked by a major transient risk factor, intermediate
among those with an associated minor reversible risk
factor, and highest among those whose thrombosis was
provoked by a persistent risk factor or who had an un-
provoked event [14-30]. Although thrombophilic abnor-
malities are risk factors for a first episode of VTE [19],
these abnormalities do not appear to play an important
role in the risk of recurrence [14,15,19,20,30-40]. Data
regarding predictive factors for recurrent VTE during
pregnancy are inconsistent and studies have not found a
clear association between the presence or absence of
transient risk factors or of a definable thrombophilia and
the risk of recurrent VTE associated with pregnancy
[12,13].
Providing thromboprophylaxis to those women at
increased risk of thrombosis can potentially reduce preg-
nancy-related recurrent VTE. However, prophylaxis dur-
ing pregnancy is problematic. Warfarin crosses the
placenta and has the potential to cause teratogenicity and
bleeding in the fetus [41-44]. Prophylactic LMWH does
not cross the placenta [45] or increase the risk of serious
adverse fetal outcomes [44-54], and does not appear to in-
crease the risk of heparin-induced thrombocytopenia
(<0.1%) or heparin-associated osteoporosis (<1%)
[46,47,51,55-68]. However, prophylactic LMWH isexpensive, inconvenient, uncomfortable to administer,
may be associated with an increased risk of major obstet-
rical bleeding [46], and generally necessitates a planned
delivery to permit epidural analgesia [46]. Additionally,
women may perceive that LMWH creates an undesirable
“medicalization” of their pregnancy.
A Cochrane systematic review [69] identified two ran-
domized trials comparing heparin prophylaxis to placebo
or no prophylaxis in pregnant women with prior VTE
[11,70]. Both suffered from major methodological weak-
nesses including very small sample sizes. Current clinical
guidelines are based primarily on the observational stud-
ies described above and indirect evidence suggesting that
LMWH substantially decreases the risk of VTE by ap-
proximately 70% in a wide variety of clinical contexts
[46,71].
In considering women’s choices of thromboprophy-
laxis during pregnancy, two considerations are of par-
ticular importance. First, treatment decisions during
pregnancy have implications not only for the health of
the mother, but also for the health of the fetus. Second,
many women prefer to see pregnancy as a normal part
of a healthy woman’s life, rather than as a medical condi-
tion. Additional considerations include the burden asso-
ciated with the management: frequency and route of
administration, pain, discomfort, and possible side
effects of the medication, and the need, frequency and
type of testing associated with a given regimen.
Given that the desirable consequences do not clearly
outweigh the undesirable consequences of prophylaxis
(or vice versa), the values and preferences of pregnant
women should be taken into consideration when making
management decisions. Because individuals have differ-
ent attitudes toward risk, the uncertainty of estimates
for both the baseline risk of recurrent VTE and the
effects of thromboprophylaxis makes the consideration
of individual preferences even more important.
There are two fundamental approaches to “patient-
specific” decision-making: (1) a holistic direct choice
procedure and (2) utility elicitation from individual
patients followed by “patient-specific” decision analysis.
The relative merit of these approaches is open to ques-
tion and few studies have addressed this issue [72]. In
the “direct choice” methods, participants are presented
with relevant health states and the probabilities asso-
ciated with occurrence of those health states under alter-
native management strategies. The most rigorous and
widely used experimental direct choice method is the
probability trade-off or probabilistic version of the
threshold technique and it involves determining the
threshold benefit at which patients accept a treatment
with fixed undesirable consequences or the threshold
toxicity or adverse effects at which patients will decline
a treatment with fixed benefit [73,74]. Investigators can
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sion board) that provide complementary information
and can ensure understanding of the probability trade-
off.
The second approach to decision-making involves
decision analytic modeling using best estimates of the
probability of occurrence of relevant health states
under the management options being considered.
Patients’ ratings of the disutility associated with rele-
vant health states (typically on scales that range from
death to full health) then inform the decision model
and allow calculations of the quality adjusted life
years associated with management options. There are
a number of approaches available for eliciting health
state evaluations [75]. The standard gamble approach
is most consistent with utility theory and is generally
preferred by health economists [76,77]. Although the
visual analog scale is theoretically less satisfactoryFigure 1 Interview flow chart.than the standard gamble, it is much easier to under-
stand, takes far less time to administer, and has su-
perior psychometric measurement properties than to
the standard gamble [78-82].
In atrial fibrillation [83,84], and to a lesser extent in
VTE and thrombolytic therapy for stroke [85], investiga-
tors have studied patients' values and preferences. A re-
cently completed systematic review of patient
preferences for antithrombotic treatment did not iden-
tify any studies of pregnant women [86]. The objective
of this study is to address this gap in knowledge.Methods
We will perform a multi-center international cross-sec-
tional interview study at six centers in four countries:
two in Hamilton, Ontario, Canada; one in Buffalo, USA;
one in Oslo, Norway; and two in Helsinki, Finland.
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Pregnant women with a history of lower extremity DVT
or PE who are considering thromboprophylaxis to prevent
recurrent antepartum VTE constitute the ideal patient
population. However, only a small number of such women
are expected to present at the six centers over the time
frame of the study. Therefore, we will also include women
with a history of lower extremity DVT or PE who are
planning pregnancy, and women who are 18 to 45 years of
age with a history of lower extremity DVT or PE and may
at some point be planning a future pregnancy. We will ex-
clude women who are currently receiving thrombopro-
phylaxis or full-dose anticoagulation, have undergone
surgical sterilization (tubal ligation or hysterectomy), have
a partner who has had a vasectomy, and those unwilling
or unable to provide informed consent.Recruitment strategy
We will prospectively identify women who are currently
pregnant or planning a pregnancy as they are referred
for counseling, and identify women with a history of
VTE with the potential to become pregnant by reviewing
patient files. We will approach women referred for con-
sideration of thromboprophylaxis prior to their consult-
ation and will make initial contact with women who are
not currently pregnant or planning a pregnancy by letter
and then by telephone.Study maneuvers
A member of the research team will meet with women
who express an interest in participating, and will explain
the purpose of the study and carry out the informed
consent process. If patients decline to participate, we will
collect the reason for refusal. If patient consent to the
study, we will make arrangements for interviews. We
will use standardized scripts developed by the research
team to ensure a standard approach across centres and
interviewers. Expert and non-expert clinicians and allied
health professionals have reviewed and revised theTable 1 Potential precipitating risk factors assessed regarding
(i.e. now resolved) risk factors within 8 weeks of initial VTE
Minor transient (i.e. now resolved)
risk factors within 8 weeks of initial VTE
Major transient
risk factors within
Pregnancy Leg
Postpartum (defined as 6 weeks after delivery) Major surgery (>30 m
ane
Hormonal contraception (birth control pill, patch
or needle)
Acute medical illness w
≥
Airplane travel (longer than 6 hours) Immobilization ≥ 3 da
was
Activscripts to ensure understandability and readability by a
lay person with a grade 9 reading level.The participant interview
Figure 1 presents the flow of the interview. We will de-
termine patients' age, educational attainment, and
current pregnancy status, as well as specific details about
their past venous thromboembolic events (including oc-
currence of PE or DVT, number of events, date of the
last event, presence or absence of precipitating risk fac-
tors prior to their event [Table 1]), known hypercoagul-
able states (Table 1), family history of VTE, type and
duration of treatment for their event(s), adverse treat-
ment effects, completeness of their recovery (for ex-
ample, presence or absence of residual chest pain or
shortness of breath, and/or residual leg swelling, pain or
discoloration), and presence or absence of prior experi-
ence with injection of prophylactic doses of LMWH dur-
ing pregnancy.Direct choice exercises
We will determine each participant’s willingness to re-
ceive LMWH prophylaxis through direct choice exer-
cises. Women will initially complete what we refer to as
the real-life scenario, followed in order by hypothetical
scenarios, the visual analog scale, the probability trade-
off exercise, a review of their answers, and finally ques-
tions to examine their understanding their understand-
ing of the scenarios. Use of decision boards will facilitate
patient understanding of the direct choice exercises.
Descriptions of each phase of the interview follow.Real life scenario We will initially present each woman
with a decision board that will include the probabilities
of developing VTE during pregnancy given the charac-
teristics of her prior VTE (see below). This scenario will
contain information similar to that received during
standard clinical care but presented in a more systematic
manner than that is typical in clinical practice.the past venous thromboembolic event Minor transient
(i.e. now resolved)
8 weeks of initial VTE
Known hypercoagulable state
casting Deficiency of antithrombin, protein C, or
protein S
inutes; general or spinal
sthesia)
Activated protein C resistance/factor V
Leiden
ith hospital admission for
3 days
Prothrombin gene mutation
ys (in bed except to go to
hroom)
Anticardiolipin antibody positivity
e cancer Nonspecific inhibitor
Table 2 Example of table presenting the risk of antepartum VTE recurrence for women considered at high risk of
recurrent VTE during pregnancy
Without low molecular
weight heparin use
With low molecular
weight heparin use
Probability of developing a blood clot during your pregnancy 5-10 in 100 1-3 in 100
Probability of NOT developing a blood clot during pregnancy 90-95 in 100 97-99 in 100
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scenarios. We will classify women as low or high risk of
recurrence. We define low risk of recurrence as the ab-
sence of a known thrombophilia and prior VTE asso-
ciated with a major transient risk factor within 8 weeks
prior to their last event, and higher risk of recurrence as
prior unprovoked VTE, VTE associated with a minor
transient risk factor within 8 weeks prior to the event or
any VTE in association with a known hypercoagulable
state. (Table 1) We estimate that the risk of antepartum
recurrence for women judged to be at lower risk lies be-
tween 0 and 5%, while that for higher risk women ranges
between 5 and 10%. We will assume that prophylactic
LMWH reduces the risk of antepartum recurrence by
approximately 70% [71]. To ensure optimal understand-
ing, we will present the risk of recurrence with and with-
out LMWH prophylaxis in three different ways: table,
bar chart and pictograph (Table 2 and Figures 2 and 3).
For the VTE health state, we will instruct women to
consider their previous venous thromboembolic event.
Women with more than one event will consider their
most recent episode. We will instruct women with previ-
ous experience in the use of prophylactic LMWH for
longer than 2 weeks during pregnancy to consider their
previous experience when making a decision. We have
prepared a description of the experience of LMWH use
throughout pregnancy for women without experience in
the use of LMWH prophylaxis during pregnancyFigure 2 Example of bar chart presentation for women considered at(Additional file 1: Appendix 1). To ensure clinical veri-
similitude, clinicians with considerable experience in the
use of LMWH in pregnant women prepared the descrip-
tion and experts in obstetrics and thromboembolism
reviewed them.
After reviewing this information, we will ask partici-
pants to decide whether or not they are willing to take
LMWH during their pregnancy (for those who are preg-
nant) or whether they would be willing to do so in a
subsequent pregnancy. Women currently pregnant and
those referred for consideration of prophylaxis with a fu-
ture pregnancy will meet with their health care provider
and may wish to discuss the information provided with
other people (for example, family members, friends, fam-
ily physician, midwife or obstetrician). We will record
the final decision after these additional consultations.
Hypothetical scenarios We will provide study partici-
pants with three standardized scenarios in which the
baseline risk of recurrent VTE, with and without the use
of LMWH (assuming a 70% relative risk reduction) [71],
will be varied (Table 3). Interviewers will show each
woman a decision board with pictograms representing a
low, followed by a medium, then a high risk of recurrent
VTE. Participants will express their willingness to use
LMWH given the associated burden (either based on
their own prior experience or the standardized descrip-
tion [Additional file 1: Appendix I]), and the absolutehigh risk of recurrent VTE during pregnancy.
Figure 3 Example of pictogram presentation for women considered at high risk of recurrent VTE during pregnancy.
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varying VTE recurrence risks.Table 3 Hypothetical scenarios with variable baseline
risks of recurrent VTE and estimates of LMWH
effectivenessProbability trade-off Interviewers will undertake prob-
ability trade-off exercises with "ping-ponging" to deter-
mine participant thresholds for accepting LMWH
prophylaxis [73,74]. We will use a scenario based on the
absolute effects of LMWH versus no prophylaxis for
prevention of recurrent VTE during nine months of
pregnancy. The interviewer will systematically vary the
risk of VTE with LMWH prophylaxis (alternating be-
tween high and low risks) to determine the minimum
acceptable reduction in the risk of VTE with prophylaxis
at which the participant would agree to initiate LMWH.
Based on the 95% CI surrounding the incidence of ante-
partum VTE in high risk patients reported in the pro-
spective cohort study [9], we estimate that the upper
bound of risk of recurrent VTE is 16 out of 100 without
prophylaxis. Therefore, we will set this risk fixed on one
side of the flipchart and will start offering probabilities
ranging from 16 fewer VTE events per 100 pregnancies
(maximum absolute risk reduction) to 0 less VTE events
(same VTE risk as no prophylaxis) on the other side of
the chart.Risk of recurrence
Low risk Medium risk High risk
Without
LMWH
4 in 100 10 in 100 16 in 100
(96 in 100 will not) (10 in 100 will not) (84 in 100 will not)
With LMWH 1 in 100 3 in 100 5 in 100
(99 in 100 will not) (97 in 100 will not) (95 in 100 will not)Visual analog scale (feeling thermometer) Inter-
viewers will determine the value patients place in rele-
vant health states using a visual analog scale called the
Feeling Thermometer (FT) [75]. When making ratings
using the FT, women choose the score on the thermom-
eter that represents the value they place on the healthstate they are evaluating. The FT is anchored at death
(0) and full health (100). We will ask participants to con-
sider (i) the health state of pregnancy with LMWH
prophylaxis using the standard description or their pre-
vious experience (for those with two weeks or more of
prophylactic LMWH during pregnancy), (ii) a pregnancy
with their own most recent VTE experience, (iii) a stan-
dardized health state with a pregnancy-related DVT, (iv)
a standardized health state with a pregnancy-related PE
and (v) a standardized health state representing an ob-
stetrical bleed (Additional file 1: Appendix I).Check for consistency and understanding
After presenting the descriptions and recording pa-
tient responses, interviewers will review participant
responses to the various exercises to check for
consistency in the participant’s choice. When inter-
viewers identify inconsistencies, they will offer parti-
cipants a chance to review and change their
responses, avoiding any suggestion that responses
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sistencies will be determined and recorded. Following this
consistency check, interviewers will ask participants two
standardized questions to evaluate their understanding of
the information provided during the interview [Additional
file 1: Appendix II]. Interviewers will also provide a rating
of the extent to which they believe the respondents had a
clear understanding of the questions and their confidence
in this assessment.
Outcomes
The primary outcome measure will be the minimum
threshold reduction in VTE risk in the probability trade-off
exercise at which women switch from declining to accept-
ing LMWH prophylaxis (which we will refer to as the
“VTE threshold”).
Secondary outcomes will include:
(i) women’s willingness to take prophylactic LMWH
according to their classification as either high or low
risk for recurrence,
(ii) women’s willingness to take prophylactic LMWH
for each of the three hypothetical scenarios
(iii) Utilities for each of the five health states assessed in
the FT (the burden of prophylactic LMWH useFigure 4 Markov state transition decision model used in analysis. This
top, the square on the left represents a “decision node” from which 2 bran
strategy leads to the same Markov node, represented by a square with the
the various potential health states that patients pass through during the m
same, the initial distribution among states and probabilities associated with
on the bottom is the modeled adverse events. During each time period or
nodes represent the chance events. For each patient, the sequence of outc
begin the next cycle.during pregnancy – either the standardized
experience or the patient’s prior experience-, a
pregnancy with the participant’s own most recent
VTE, a standardized description of pregnancy-
related DVT, a standardized description of
pregnancy-related PE, and a standardized
description of an obstetrical bleed [Additional file 1:
Appendix I]).
Analysis
Baseline characteristics
We will describe age, educational attainment, pregnancy
status, number and characteristics of previous venous
thromboembolic events, presence or absence of precipi-
tating risk factors, and prior experience with prophylac-
tic LMWH injections using means and standard
deviations or proportions, as appropriate.
Primary and secondary outcome(s)
We will calculate the mean threshold reduction in VTE
at which women were willing to accept use of LMWH
and the 95% confidence interval around the mean. We
will calculate the proportion of women who are willing
to take prophylactic LMWH and the associated 95%diagram depicts the model used in the analysis. In the figure on the
ches, representing alternative management strategies emanate. Each
“∞” symbol. The branches leading from the Markov node represent
odel simulation. Although the potential states for each strategy are the
transitions between states will differ between strategies. The figure
“cycle”, modeled patients are at risk for various adverse events. Round
omes at these “chance” nodes will determine the state at which they
Table 4 Guidelines for frequencies of inconsistent
responses favoring review of study scripts and
presentation tools
Frequency of inconsistent response % Lower bound of 95% CI
> or = 5/10 50.0 23.7
> or = 8/20 40.0 21.9
> or = 10/30 33.3 19.2
> or = 12/40 30.0 18.1
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the visual analog scale ratings for each health state will
also be determined.
Multiple variable linear regression will be undertaken
to explore determinants of the VTE threshold, as deter-
mined in the probability trade-off exercise. In this ana-
lysis, VTE threshold will be the dependent variable and
the independent variables will be the previous experi-
ence of VTE (categorized as severe, moderate, or mild),
previous experience with prophylactic LMWH (yes,
problematic; yes, no problems; no prior experience),
level of education (some postsecondary versus no post-
secondary) and study site.
We will perform a standard multiple variable logistic
regression to explore the determinants on the choice for
or against LMWH prophylaxis in the real life scenario.
The dependent variable will be the choice for or against
LMWH prophylaxis and the independent variables will
be the previous experience of VTE, previous experience
with LMWH prophylaxis, level of education, study site,
and high or low risk for recurrence.
A hierarchical logistic regression in which the
dependent variable will be the choice to receive or not
receive LMWH from the results of the hypothetical sce-
nario exercise will also be undertaken. The independent
variable within the first level will be the magnitude of
the absolute risk reduction (high, moderate and low).
The second level, nested within the absolute risk reduc-
tion will include previous experience of VTE, previous
experience with LMWH, level of education and study
site. Finally, we will perform a multiple variable linear
regression with the threshold as the dependent variable
and with utilities as independent variables. We will
evaluate the interaction term of utilities and VTE in the
regression model.
Using an independent sample t-test, we will evaluate if
the responses between women who are pregnant or
planning a pregnancy are different to those who are not.
The scatter plots of each of the participants’ utilities, as
determined by the FT ratings of the health states, and the
VTE thresholds will be examined to evaluate the relation
between participant utilities and their VTE threshold. We
will calculate Pearson’s correlations between each of the
utilities for the health states and the threshold.
We believe that a lack of consistency in patient
responses is the best way to detect a problem with indi-
vidual patient understanding, which if it occurs fre-
quently enough (i.e. > or = 25% of participants), may
represent a problem in the way in which the information
is being presented. Therefore, we will review consistency
data after 10, 20, 30, and 40 women have been enrolled.
We will also examine consistency data prior to these
pre-specified points if there is concern about the level of
inconsistency in patient responses. Table 4 containsfrequencies of inconsistent responses, which would favor
a review of the study scripts and presentation tools. We
will also compare responses between women who are
consistent and those who are inconsistent in their
responses, even after they are provided with the oppor-
tunity to correct discrepancies in their responses. If the
results differ between these groups, our primary analysis
will include only those with consistent responses.
For all key analyses above, we will compare results and
the pattern of responses in women who answer the
“understanding” questions correctly and those who do
not. A similar comparison will also be made according
to the interviewer’s impression of patient understanding.
If the results differ between women categorized as
understanding and not understanding, our primary ana-
lysis will focus on women with an apparent high level of
understanding.
Finally, we will perform a “personalized decision ana-
lysis” for each woman in the study. We will update a
prior decision analytic model examining prophylactic
LMWH in pregnant women with a history of prior VTE
(Figure 4) [87], using each women’s visual analog scale
utility assessments for the relevant outcomes of DVT in
pregnancy, PE in pregnancy, obstetrical hemorrhage and
the burden of LWMH prophylaxis in pregnancy. Given
that the risk of heparin-induced thrombocytopenia
(<0.1%) and heparin associated osteoporosis (<1%) are
either not increased or minimally increased with prophy-
lactic LMWH [65,68], we will not consider these health
states in the decision analysis. We will place the health
state utilities in the decision model for each woman’s
current situation and the three hypothetical scenarios.
We will compare the decision model’s results with the
VTE threshold selected in the probability trade-off tasks.
Sample size
Previous research from our group in patients with atrial
fibrillation [83], and from other groups studying non-
pregnant women with prior VTE [85], suggests that
moderately precise estimates of patient preference can
be obtained with sample sizes of approximately 100 par-
ticipants. In the most relevant recent experience, co-
investigators on the current project enrolled 96 patients
with risk factors of atrial fibrillation [85]. The primary
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bleeds patients were willing to accept over 2 years given
a reduction of 3 strokes over a 2-year period. This is dir-
ectly analogous to the primary endpoint of our study,
the VTE threshold. In the atrial fibrillation study, the
mean number of bleeds that patients were willing to
accept was 15. With a sample size of 96 patients, the
confidence interval around the mean number of accept-
able bleeds was 12 to 18, which we judged to be an ac-
ceptable range of uncertainty. The range of bleeds that
patients chose varied over an extremely wide range
(from 0 to 100). The entire range of possible VTE pre-
vented for LWMH to be acceptable in the current study
will range from 0 to 16, a much narrower range, which
is certain to result in much smaller variability, and thus
an appreciably smaller confidence interval. We are, thus,
confident that our projected sample size of 100 will yield
a sufficiently precise estimate of our primary outcome,
the mean number of VTE prevented required to tolerate
LMWH.
Safety and ethical considerations
This study does not pose any safety risks to participating
women. Research Ethics Board approval has been
obtained in Canada (Hamilton Health Sciences), Finland
(The Coordinating Ethics Committee of Helsinki and
Uusimaa Hospital District) and USA (Institutional Re-
view Board of the State University of New York at Buf-
falo), and will be obtained from all other participating
sites. All women will provide written informed consent
prior to participating in this study.
Discussion
Producing guidelines for management of pregnant
women with prior VTE is problematic because there
is little reliable information in the literature to guide
the value and preference judgments necessary for
making recommendations. Clinical management is
challenging because of the lack of a standardized ap-
proach to presenting information and eliciting
patients' choice. Our study will be the first to explore
the preferences of women at risk of pregnancy-related
VTE with respect to the use of antithrombotic
therapy.
Our study has several strengths. We will address
some of the limitations of the previous studies in
the field of decision-making. These studies using dir-
ect choice methods, and in particular the probability
trade-off, have shown many extreme choices that
raise doubts about whether all patients understood
the decisions they were making [84,88]. We pilot-
tested standardized scripts that were reviewed by ex-
pert and non-expert clinicians, and allied health pro-
fessionals to ensure appropriate readability andunderstandability. We are presenting probability in-
formation in three different ways. We have trained
research assistants and will undertake quality control
of the data as it accumulates.
We will check for consistency in the participants’
choice to either take or not take LMWH for a given
probability of DVT. Participants will have discrepancies
brought to their attention and will have the opportunity
to change their responses. We will use standardized
questions to test understanding of the information pre-
sented and the interviewer will provide a rating of the
extent to which she or he believes the respondent had a
clear understanding of the questions and their confi-
dence in this assessment. Our analysis will include an
exploration of whether patterns of responses differ (1)
between those with an apparently high level of under-
standing and those who do not, (2) between those whose
answers are consistent and those with inconsistent
answers, and (3) between those who, according to the
interviewer’s impression of patient understanding, show
a correct understanding and those who do not. Finally,
our multicenter international design limits the influence
of local views about the use of LMWH prophylaxis for
prevention of recurrent pregnancy-associated VTE and
enhances generalizability.
Our study has some potential limitations. Our sample
includes women not contemplating becoming pregnant.
There are logistical challenges in prospectively identify-
ing such a group and in ensuring their participation
prior to their receiving other information about their
choice. We believe that the inclusion of these women is
a reasonable given the proximity to the necessity of a
choice for these women and that their responses will re-
flect their true, thoughtful preferences. We will, never-
theless, evaluate whether the responses between women
who are pregnant or planning a pregnancy are different
to those who are not.
The research outlined in this protocol aims to provide
explicit, quantitative expressions of women's valuations
of health states related to recurrent VTE and its preven-
tion with LMWH. This information will improve the
quality of formal decision analyses evaluating whether
the effectiveness of prophylaxis outweighs risks and bur-
den of therapy and provide relevant information for
guideline developers providing recommendations for
clinical practice.
Our protocol addresses some of the limitations of
the previous studies in the field of decision-making
and describes innovative approaches to checking for
understanding and systematically exploring inconsist-
encies. The methods described in this protocol are
novel and rigorous, and could be utilized immedi-
ately by those working in the area of optimizing
patients' medical decision-making.
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